Tessari Eben's most recent trade in Kiniksa Pharmaceuticals Ltd - Ordinary Shares - Class A was a trade of 17,300 Class A Ordinary Share done at an average price of $28.3 . Disclosure was reported to the exchange on June 16, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Kiniksa Pharmaceuticals Lt... | Eben Tessari | CHIEF OPERATING OFFICER | Sale of securities on an exchange or to another person at price $ 28.28 per share. | 16 Jun 2025 | 17,300 | 61,563 (0%) | 0% | 28.3 | 489,244 | Class A Ordinary Share |
| Kiniksa Pharmaceuticals Lt... | Eben Tessari | CHIEF OPERATING OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Jun 2025 | 6,500 | 38,500 | - | - | Share Option | |
| Kiniksa Pharmaceuticals Lt... | Eben Tessari | CHIEF OPERATING OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 8.83 per share. | 16 Jun 2025 | 6,500 | 78,863 (0%) | 0% | 8.8 | 57,395 | Class A Ordinary Share |
| Kiniksa Pharmaceuticals Lt... | Eben Tessari | CHIEF OPERATING OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Jun 2025 | 45,042 | 38,928 | - | - | Share Option | |
| Kiniksa Pharmaceuticals Lt... | Eben Tessari | CHIEF OPERATING OFFICER | Sale of securities on an exchange or to another person at price $ 30.51 per share. | 09 Jun 2025 | 45,042 | 72,363 (0%) | 0% | 30.5 | 1,374,231 | Class A Ordinary Share |
| Kiniksa Pharmaceuticals Lt... | Eben Tessari | CHIEF OPERATING OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 10.36 per share. | 09 Jun 2025 | 45,042 | 117,405 (0%) | 0% | 10.4 | 466,635 | Class A Ordinary Share |
| Kiniksa Pharmaceuticals Lt... | Eben Tessari | CHIEF OPERATING OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Jun 2025 | 15,506 | 83,970 | - | - | Share Option | |
| Kiniksa Pharmaceuticals Lt... | Eben Tessari | CHIEF OPERATING OFFICER | Sale of securities on an exchange or to another person at price $ 30.46 per share. | 09 Jun 2025 | 15,506 | 72,363 (0%) | 0% | 30.5 | 472,313 | Class A Ordinary Share |
| Kiniksa Pharmaceuticals Lt... | Eben Tessari | CHIEF OPERATING OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 10.36 per share. | 09 Jun 2025 | 15,506 | 87,869 (0%) | 0% | 10.4 | 160,642 | Class A Ordinary Share |
| Kiniksa Pharmaceuticals Lt... | Eben Tessari | CHIEF OPERATING OFFICER | Sale of securities on an exchange or to another person at price $ 30.38 per share. | 09 Jun 2025 | 10,319 | 72,363 (0%) | 0% | 30.4 | 313,491 | Class A Ordinary Share |
| Kiniksa Pharmaceuticals Lt... | Eben Tessari | CHIEF OPERATING OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Jun 2025 | 10,319 | 99,476 | - | - | Share Option | |
| Kiniksa Pharmaceuticals Lt... | Eben Tessari | CHIEF OPERATING OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 10.36 per share. | 09 Jun 2025 | 10,319 | 82,682 (0%) | 0% | 10.4 | 106,905 | Class A Ordinary Share |
| Kiniksa Pharmaceuticals Lt... | Eben Tessari | CHIEF OPERATING OFFICER | Sale of securities on an exchange or to another person at price $ 26.41 per share. | 19 May 2025 | 12,000 | 72,363 (0%) | 0% | 26.4 | 316,920 | Class A Ordinary Share |
| Kiniksa Pharmaceuticals Lt... | Eben Tessari | CHIEF OPERATING OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 19 May 2025 | 7,000 | 49 | - | - | Share Option | |
| Kiniksa Pharmaceuticals Lt... | Eben Tessari | CHIEF OPERATING OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.80 per share. | 19 May 2025 | 7,000 | 84,363 (0%) | 0% | 3.8 | 26,600 | Class A Ordinary Share |
| Kiniksa Pharmaceuticals Lt... | Eben Tessari | CHIEF OPERATING OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 May 2025 | 8,302 | 8,302 | - | - | Performance Share Option | |
| Kiniksa Pharmaceuticals Lt... | Eben Tessari | CHIEF OPERATING OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 May 2025 | 8,042 | 8,042 | - | - | Performance Share Option | |
| Kiniksa Pharmaceuticals Lt... | Eben Tessari | CHIEF OPERATING OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 May 2025 | 5,224 | 5,224 | - | - | Performance Share Unit | |
| Kiniksa Pharmaceuticals Lt... | Eben Tessari | CHIEF OPERATING OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 May 2025 | 4,975 | 4,975 | - | - | Performance Share Unit | |
| Kiniksa Pharmaceuticals Lt... | Eben Tessari | CHIEF OPERATING OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Apr 2025 | 7,000 | 7,049 | - | - | Share Option | |
| Kiniksa Pharmaceuticals Lt... | Eben Tessari | CHIEF OPERATING OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.80 per share. | 14 Apr 2025 | 7,000 | 89,363 (0%) | 0% | 3.8 | 26,600 | Class A Ordinary Share |
| Kiniksa Pharmaceuticals Lt... | Eben Tessari | CHIEF OPERATING OFFICER | Sale of securities on an exchange or to another person at price $ 20.74 per share. | 14 Apr 2025 | 6,421 | 77,363 (0%) | 0% | 20.7 | 133,172 | Class A Ordinary Share |
| Kiniksa Pharmaceuticals Lt... | Eben Tessari | CHIEF OPERATING OFFICER | Sale of securities on an exchange or to another person at price $ 20.19 per share. | 14 Apr 2025 | 5,579 | 83,784 (0%) | 0% | 20.2 | 112,640 | Class A Ordinary Share |
| Kiniksa Pharmaceuticals Lt... | Eben Tessari | CHIEF OPERATING OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 07 Apr 2025 | 2,726 | 2,726 | - | - | Restricted Share Unit | |
| Kiniksa Pharmaceuticals Lt... | Eben Tessari | CHIEF OPERATING OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 07 Apr 2025 | 2,726 | 83,164 (0%) | 0% | - | Class A Ordinary Share | |
| Kiniksa Pharmaceuticals Lt... | Eben Tessari | CHIEF OPERATING OFFICER | Payment of exercise price or tax liability using portion of securities received from the company at price $ 20.28 per share. | 07 Apr 2025 | 801 | 82,363 (0%) | 0% | 20.3 | 16,244 | Class A Ordinary Share |
| Kiniksa Pharmaceuticals Lt... | Eben Tessari | CHIEF OPERATING OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Apr 2025 | 39,364 | 39,364 | - | - | Share Option | |
| Kiniksa Pharmaceuticals Lt... | Eben Tessari | CHIEF OPERATING OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Apr 2025 | 19,657 | 19,657 | - | - | Performance Share Unit | |
| Kiniksa Pharmaceuticals Lt... | Eben Tessari | CHIEF OPERATING OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Apr 2025 | 9,828 | 9,828 | - | - | Restricted Share Unit | |
| Kiniksa Pharmaceuticals Lt... | Eben Tessari | CHIEF OPERATING OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Apr 2025 | 1,773 | 79,726 (0%) | 0% | - | Class A Ordinary Share | |
| Kiniksa Pharmaceuticals Lt... | Eben Tessari | CHIEF OPERATING OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Apr 2025 | 1,773 | 3,545 | - | - | Restricted Share Unit | |
| Kiniksa Pharmaceuticals Lt... | Eben Tessari | CHIEF OPERATING OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Apr 2025 | 1,746 | 5,235 | - | - | Restricted Share Unit | |
| Kiniksa Pharmaceuticals Lt... | Eben Tessari | CHIEF OPERATING OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Apr 2025 | 1,746 | 81,472 (0%) | 0% | - | Class A Ordinary Share | |
| Kiniksa Pharmaceuticals Lt... | Eben Tessari | CHIEF OPERATING OFFICER | Payment of exercise price or tax liability using portion of securities received from the company at price $ 21.77 per share. | 01 Apr 2025 | 521 | 80,951 (0%) | 0% | 21.8 | 11,342 | Class A Ordinary Share |
| Kiniksa Pharmaceuticals Lt... | Eben Tessari | CHIEF OPERATING OFFICER | Payment of exercise price or tax liability using portion of securities received from the company at price $ 21.77 per share. | 01 Apr 2025 | 513 | 80,438 (0%) | 0% | 21.8 | 11,168 | Class A Ordinary Share |
| Kiniksa Pharmaceuticals Lt... | Eben Tessari | CHIEF OPERATING OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Mar 2025 | 1,964 | 78,530 (0%) | 0% | - | Class A Ordinary Share | |
| Kiniksa Pharmaceuticals Lt... | Eben Tessari | CHIEF OPERATING OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Mar 2025 | 1,964 | 0 | - | - | Restricted Share Unit | |
| Kiniksa Pharmaceuticals Lt... | Eben Tessari | CHIEF OPERATING OFFICER | Payment of exercise price or tax liability using portion of securities received from the company at price $ 22.61 per share. | 16 Mar 2025 | 577 | 77,953 (0%) | 0% | 22.6 | 13,046 | Class A Ordinary Share |
| Kiniksa Pharmaceuticals Lt... | Eben Tessari | CHIEF OPERATING OFFICER | Sale of securities on an exchange or to another person at price $ 21.06 per share. | 10 Mar 2025 | 12,409 | 76,566 (0%) | 0% | 21.1 | 261,334 | Class A Ordinary Share |
| Kiniksa Pharmaceuticals Lt... | Eben Tessari | CHIEF OPERATING OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.80 per share. | 10 Mar 2025 | 7,000 | 88,975 (0%) | 0% | 3.8 | 26,600 | Class A Ordinary Share |
| Kiniksa Pharmaceuticals Lt... | Eben Tessari | CHIEF OPERATING OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Mar 2025 | 7,000 | 14,049 | - | - | Share Option | |
| Kiniksa Pharmaceuticals Lt... | Eben Tessari | CHIEF OPERATING OFFICER | Sale of securities on an exchange or to another person at price $ 19.57 per share. | 10 Feb 2025 | 14,000 | 81,975 (0%) | 0% | 19.6 | 273,980 | Class A Ordinary Share |
| Kiniksa Pharmaceuticals Lt... | Eben Tessari | CHIEF OPERATING OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.80 per share. | 10 Feb 2025 | 7,000 | 95,975 (0%) | 0% | 3.8 | 26,600 | Class A Ordinary Share |
| Kiniksa Pharmaceuticals Lt... | Eben Tessari | CHIEF OPERATING OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Feb 2025 | 7,000 | 21,049 | - | - | Share Option | |
| Kiniksa Pharmaceuticals Lt... | Eben Tessari | CHIEF OPERATING OFFICER | Sale of securities on an exchange or to another person at price $ 18.13 per share. | 13 Jan 2025 | 12,323 | 90,652 (0%) | 0% | 18.1 | 223,416 | Class A Ordinary Share |
| Kiniksa Pharmaceuticals Lt... | Eben Tessari | CHIEF OPERATING OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.80 per share. | 13 Jan 2025 | 7,000 | 102,975 (0%) | 0% | 3.8 | 26,600 | Class A Ordinary Share |
| Kiniksa Pharmaceuticals Lt... | Eben Tessari | CHIEF OPERATING OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Jan 2025 | 7,000 | 28,049 | - | - | Share Option | |
| Kiniksa Pharmaceuticals Lt... | Eben Tessari | CHIEF OPERATING OFFICER | Sale of securities on an exchange or to another person at price $ 19.08 per share. | 13 Jan 2025 | 1,677 | 88,975 (0%) | 0% | 19.1 | 31,997 | Class A Ordinary Share |
| Kiniksa Pharmaceuticals Lt... | Tessari Eben | CHIEF OPERATING OFFICER | Sale of securities on an exchange or to another person at price $ 20.44 per share. | 16 Dec 2024 | 23,017 | 95,975 (0%) | 0% | 20.4 | 470,467 | Class A Ordinary Share |
| Kiniksa Pharmaceuticals Lt... | Tessari Eben | CHIEF OPERATING OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.59 per share. | 16 Dec 2024 | 16,017 | 118,992 (0%) | 0% | 1.6 | 25,467 | Class A Ordinary Share |
| Kiniksa Pharmaceuticals Lt... | Tessari Eben | CHIEF OPERATING OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Dec 2024 | 16,017 | 0 | - | - | Share Option | |
| Kiniksa Pharmaceuticals Lt... | Eben Tessari | CHIEF OPERATING OFFICER | Sale of securities on an exchange or to another person at price $ 21.04 per share. | 18 Nov 2024 | 17,000 | 102,975 (0%) | 0% | 21.0 | 357,680 | Class A Ordinary Share |
| Kiniksa Pharmaceuticals Lt... | Eben Tessari | CHIEF OPERATING OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 Nov 2024 | 10,000 | 16,017 | - | - | Share Option | |
| Kiniksa Pharmaceuticals Lt... | Eben Tessari | CHIEF OPERATING OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.59 per share. | 18 Nov 2024 | 10,000 | 119,975 (0%) | 0% | 1.6 | 15,900 | Class A Ordinary Share |
| Kiniksa Pharmaceuticals Lt... | Eben Tessari | CHIEF OPERATING OFFICER | Sale of securities on an exchange or to another person at price $ 26.87 per share. | 15 Oct 2024 | 17,000 | 109,975 (0%) | 0% | 26.9 | 456,790 | Class A Ordinary Share |
| Kiniksa Pharmaceuticals Lt... | Eben Tessari | CHIEF OPERATING OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Oct 2024 | 10,000 | 26,017 | - | - | Share Option | |
| Kiniksa Pharmaceuticals Lt... | Eben Tessari | CHIEF OPERATING OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.59 per share. | 15 Oct 2024 | 10,000 | 126,975 (0%) | 0% | 1.6 | 15,900 | Class A Ordinary Share |
| Kiniksa Pharmaceuticals Lt... | Eben Tessari | CHIEF OPERATING OFFICER | Sale of securities on an exchange or to another person at price $ 24.99 per share. | 23 Sep 2024 | 17,500 | 116,975 (0%) | 0% | 25.0 | 437,325 | Class A Ordinary Share |
| Kiniksa Pharmaceuticals Lt... | Eben Tessari | CHIEF OPERATING OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.59 per share. | 23 Sep 2024 | 10,000 | 134,475 (0%) | 0% | 1.6 | 15,900 | Class A Ordinary Share |
| Kiniksa Pharmaceuticals Lt... | Eben Tessari | CHIEF OPERATING OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 23 Sep 2024 | 10,000 | 36,017 | - | - | Share Option | |
| Kiniksa Pharmaceuticals Lt... | Eben Tessari | CHIEF OPERATING OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Sep 2024 | 36,300 | 36,300 | - | - | Share Option | |
| Kiniksa Pharmaceuticals Lt... | Eben Tessari | CHIEF OPERATING OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Sep 2024 | 6,981 | 6,981 | - | - | Restricted Share Unit | |
| Kiniksa Pharmaceuticals Lt... | Eben Tessari | CHIEF OPERATING OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Sep 2024 | 4,499 | 124,410 (0%) | 0% | - | Class A Ordinary Share | |
| Kiniksa Pharmaceuticals Lt... | Eben Tessari | CHIEF OPERATING OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Sep 2024 | 2,726 | 5,452 | - | - | Restricted Share Unit | |
| Kiniksa Pharmaceuticals Lt... | Eben Tessari | CHIEF OPERATING OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Sep 2024 | 1,964 | 1,964 | - | - | Restricted Share Unit | |
| Kiniksa Pharmaceuticals Lt... | Eben Tessari | CHIEF OPERATING OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Sep 2024 | 1,964 | 125,052 (0%) | 0% | 0 | Class A Ordinary Share | |
| Kiniksa Pharmaceuticals Lt... | Eben Tessari | CHIEF OPERATING OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Sep 2024 | 1,773 | 5,318 | - | - | Restricted Share Unit | |
| Kiniksa Pharmaceuticals Lt... | Eben Tessari | CHIEF OPERATING OFFICER | Payment of exercise price or tax liability using portion of securities received from the company at price $ 26.74 per share. | 01 Sep 2024 | 1,322 | 123,088 (0%) | 0% | 26.7 | 35,350 | Class A Ordinary Share |
| Kiniksa Pharmaceuticals Lt... | Eben Tessari | CHIEF OPERATING OFFICER | Payment of exercise price or tax liability using portion of securities received from the company at price $ 26.74 per share. | 01 Sep 2024 | 577 | 124,475 (0%) | 0% | 26.7 | 15,429 | Class A Ordinary Share |
| Kiniksa Pharmaceuticals Lt... | Eben Tessari | CHIEF OPERATING OFFICER | Sale of securities on an exchange or to another person at price $ 26.91 per share. | 27 Aug 2024 | 17,500 | 119,911 (0%) | 0% | 26.9 | 470,925 | Class A Ordinary Share |
| Kiniksa Pharmaceuticals Lt... | Eben Tessari | CHIEF OPERATING OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 27 Aug 2024 | 10,000 | 46,017 | - | - | Share Option | |
| Kiniksa Pharmaceuticals Lt... | Eben Tessari | CHIEF OPERATING OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.59 per share. | 27 Aug 2024 | 10,000 | 137,411 (0%) | 0% | 1.6 | 15,900 | Class A Ordinary Share |
| Kiniksa Pharmaceuticals Lt... | Eben Tessari | CHIEF OPERATING OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Apr 2024 | 36,300 | 36,300 | - | - | Share Option | |
| Kiniksa Pharmaceuticals Lt... | Eben Tessari | CHIEF OPERATING OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Apr 2024 | 6,981 | 12,299 | - | - | Restricted Share Unit | |
| Kiniksa Pharmaceuticals Lt... | Eben Tessari | CHIEF OPERATING OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Apr 2024 | 5,585 | 5,585 | - | - | Performance Share Unit | |
| Kiniksa Pharmaceuticals Lt... | Eben Tessari | CHIEF OPERATING OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 04 Apr 2024 | 2,726 | 9,573 | - | - | Restricted Share Unit | |
| Kiniksa Pharmaceuticals Lt... | Eben Tessari | CHIEF OPERATING OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 04 Apr 2024 | 2,726 | 126,825 (0%) | 0% | - | Class A Common Share | |
| Kiniksa Pharmaceuticals Lt... | Eben Tessari | CHIEF OPERATING OFFICER | Payment of exercise price or tax liability using portion of securities received from the company at price $ 17.90 per share. | 04 Apr 2024 | 801 | 126,024 (0%) | 0% | 17.9 | 14,338 | Class A Common Share |
| Kiniksa Pharmaceuticals Lt... | Eben Tessari | CHIEF OPERATING OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Apr 2024 | 1,773 | 5,318 | - | - | Restricted Share Unit | |
| Kiniksa Pharmaceuticals Lt... | Eben Tessari | CHIEF OPERATING OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Apr 2024 | 1,773 | 124,620 (0%) | 0% | - | Class A Common Share | |
| Kiniksa Pharmaceuticals Lt... | Eben Tessari | CHIEF OPERATING OFFICER | Payment of exercise price or tax liability using portion of securities received from the company at price $ 19.70 per share. | 01 Apr 2024 | 521 | 124,099 (0%) | 0% | 19.7 | 10,264 | Class A Common Share |
| Kiniksa Pharmaceuticals Lt... | Eben Tessari | CHIEF OPERATING OFFICER | Sale of securities on an exchange or to another person at price $ 22.03 per share. | 01 Mar 2024 | 1,189 | 122,847 (0%) | 0% | 22.0 | 26,194 | Class A Common Share |
| Kiniksa Pharmaceuticals Lt... | Eben Tessari | CHIEF OPERATING OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.59 per share. | 01 Mar 2024 | 656 | 124,036 (0%) | 0% | 1.6 | 1,043 | Class A Common Share |
| Kiniksa Pharmaceuticals Lt... | Eben Tessari | CHIEF OPERATING OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Mar 2024 | 656 | 56,017 | - | - | Share Option | |
| Kiniksa Pharmaceuticals Lt... | Eben Tessari | CHIEF OPERATING OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Apr 2023 | 2,727 | 120,868 (0%) | 0% | - | Class A Common Share | |
| Kiniksa Pharmaceuticals Lt... | Eben Tessari | CHIEF OPERATING OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Apr 2023 | 2,727 | 8,178 | - | - | Restricted Share Unit | |
| Kiniksa Pharmaceuticals Lt... | Eben Tessari | CHIEF OPERATING OFFICER | Payment of exercise price or tax liability using portion of securities received from the company at price $ 10.71 per share. | 10 Apr 2023 | 801 | 120,067 (0%) | 0% | 10.7 | 8,579 | Class A Common Share |
| Kiniksa Pharmaceuticals Lt... | Eben Tessari | CHIEF OPERATING OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Apr 2023 | 42,544 | 42,544 | - | - | Share Option | |
| Kiniksa Pharmaceuticals Lt... | Eben Tessari | CHIEF OPERATING OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Apr 2023 | 7,091 | 7,091 | - | - | Restricted Share Unit | |
| Kiniksa Pharmaceuticals Lt... | Eben Tessari | CHIEF OPERATING OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Mar 2023 | 2,982 | 0 | - | - | Restricted Share Unit | |
| Kiniksa Pharmaceuticals Lt... | Eben Tessari | CHIEF OPERATING OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Mar 2023 | 2,982 | 119,017 (0%) | 0% | - | Class A Common Share | |
| Kiniksa Pharmaceuticals Lt... | Eben Tessari | CHIEF OPERATING OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Mar 2023 | 1,964 | 116,612 (0%) | 0% | - | Class A Common Share | |
| Kiniksa Pharmaceuticals Lt... | Eben Tessari | CHIEF OPERATING OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Mar 2023 | 1,964 | 3,928 | - | - | Restricted Share Unit | |
| Kiniksa Pharmaceuticals Lt... | Eben Tessari | CHIEF OPERATING OFFICER | Payment of exercise price or tax liability using portion of securities received from the company at price $ 11.12 per share. | 16 Mar 2023 | 876 | 118,141 (0%) | 0% | 11.1 | 9,741 | Class A Common Share |
| Kiniksa Pharmaceuticals Lt... | Eben Tessari | CHIEF OPERATING OFFICER | Payment of exercise price or tax liability using portion of securities received from the company at price $ 11.46 per share. | 16 Mar 2023 | 577 | 116,035 (0%) | 0% | 11.5 | 6,612 | Class A Common Share |
| Kiniksa Pharmaceuticals Lt... | Eben Tessari | CHIEF OPERATING OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Sep 2022 | 65,420 | 65,420 | - | - | Share Option | |
| Kiniksa Pharmaceuticals Lt... | Eben Tessari | CHIEF OPERATING OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Sep 2022 | 10,905 | 10,905 | - | - | Restricted Share Unit | |
| Kiniksa Pharmaceuticals Lt... | Eben Tessari | CHIEF OPERATING OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Sep 2022 | 1,964 | 5,892 | - | - | Restricted Share Unit | |
| Kiniksa Pharmaceuticals Lt... | Eben Tessari | CHIEF OPERATING OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Sep 2022 | 1,964 | 115,225 (0%) | 0% | - | Class A Common Share | |
| Kiniksa Pharmaceuticals Lt... | Eben Tessari | CHIEF OPERATING OFFICER | Grant, award, or other acquisition of securities at price $ 9.56 per share. | 01 Sep 2022 | 1,048 | 113,261 (0%) | 0% | 9.6 | 10,019 | Class A Common Share |
| Kiniksa Pharmaceuticals Lt... | Eben Tessari | CHIEF OPERATING OFFICER | Payment of exercise price or tax liability using portion of securities received from the company at price $ 11.44 per share. | 01 Sep 2022 | 577 | 114,648 (0%) | 0% | 11.4 | 6,601 | Class A Common Share |